Advanced search
Publication Cover
OncoImmunology Volume 9, 2020 - Issue 1
Submit an article Journal homepage
3,188
Views
29
CrossRef citations to date
0
Altmetric
Back Matter

The prognostic impact of immune-related adverse events during anti-PD1 treatment in melanoma and non–small-cell lung cancer: a real-life retrospective study

R. Duponta Service de Médecine interne et immunologie clinique, Hôpital Rangueil, CHU de Toulouse, Université Paul Sabatier-Toulouse III, Université de Toulouse, Toulouse, FranceCorrespondence[email protected]
,
E. Bérardb Service d’Epidémiologie, CHU de Toulouse, UMR 1027, INSERM-Université de Toulouse, Toulouse, France
,
F. Puissetc Pharmacie, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, France
,
T. Comontd Médecine interne et immunopathologie clinique, Institut Universitaire du Cancer de Toulouse – Oncopole, CHU de Toulouse, Toulouse, France
,
J.-P. Delorde Département d’Oncologie Médicale, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse – Oncopole, Toulouse, France
,
R. Guimbaudf Service d’Oncologie, Hôpital Rangueil, CHU de Toulouse, Université Paul Sabatier-Toulouse III, Université de Toulouse, Toulouse, France;g INSERM UMR 1037, CRCT, Université Paul Sabatier-Toulouse III, Université de Toulouse, Toulouse, France
,
N. Meyerg INSERM UMR 1037, CRCT, Université Paul Sabatier-Toulouse III, Université de Toulouse, Toulouse, France;h Oncodermatologie, Institut Universitaire du Cancer de Toulouse – Oncopole et CHU de Toulouse, Université Paul Sabatier-Toulouse III, Université de Toulouse, Toulouse, France
,
J. Mazieresi Service de Pneumologie, Hôpital Larrey, CHU de Toulouse, Université Paul Sabatier-Toulouse III, Université de Toulouse, Toulouse, France
&
L. Alrica Service de Médecine interne et immunologie clinique, Hôpital Rangueil, CHU de Toulouse, Université Paul Sabatier-Toulouse III, Université de Toulouse, Toulouse, France;j UMR 152 IRD - Université Paul Sabatier-Toulouse III, Université de Toulouse, Toulouse, FranceCorrespondence[email protected]
 show all
Article: 1682383 | Received 05 Sep 2019, Accepted 14 Oct 2019, Published online: 05 Nov 2019

Citations (29)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Yu Zhou, Haizhu Chen, Le Tang, Yu Feng, Yunxia Tao, Liling Huang, Ning Lou & Yuankai Shi. (2023) Association of Immune-Related Adverse Events and Efficacy in Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. Immunotherapy 15:3, pages 209-220.
Read now
Filippo Gustavo Dall’Olio, Alessandro Rizzo, Veronica Mollica, Maria Massucci, Ilaria Maggio & Francesco Massari. (2021) Immortal Time Bias in the Association Between Toxicity and Response for Immune Checkpoint Inhibitors: A Meta-Analysis. Immunotherapy 13:3, pages 257-270.
Read now
Sandra G. Williams, Arash Mollaeian, James D. Katz & Sarthak Gupta. (2020) Immune checkpoint inhibitor-induced inflammatory arthritis: identification and management. Expert Review of Clinical Immunology 16:8, pages 771-785.
Read now
Julie Le Naour, Laurence Zitvogel, Lorenzo Galluzzi, Erika Vacchelli & Guido Kroemer. (2020) Trial watch: STING agonists in cancer therapy. OncoImmunology 9:1.
Read now

Articles from other publishers (25)

Carmen Maria Valencia Soto, María Victoria Villacañas Palomares, Adela Garcia-Avello Fernández-Cueto, Sara Barbadillo Villanueva, Virginia Martínez Callejo, María Ochagavía Sufrategui, Pedro Muñoz Cacho & Marta Valero Domínguez. (2024) Predictive value of immune-related adverse events during pembrolizumab treatment in non-small cell lung cancer. European Journal of Hospital Pharmacy 31:1, pages 40-45.
Crossref
Fan Tong, Yi Sun, Yahui Zhu, Huizi Sha, Jiayao Ni, Liang Qi, Qing Gu, Chan Zhu, Wenjing Xi, Baorui Liu, Weiwei Kong & Juan Du. (2023) Making “cold” tumors “hot”- radiotherapy remodels the tumor immune microenvironment of pancreatic cancer to benefit from immunotherapy: a case report. Frontiers in Immunology 14.
Crossref
Li Lin, Yu Liu, Chen Chen, Anhua Wei & Wei Li. (2023) Association between immune-related adverse events and immunotherapy efficacy in non-small-cell lung cancer: a meta-analysis. Frontiers in Pharmacology 14.
Crossref
Kim Koczka, Rodrigo Rigo, Eugene Batuyong, Sara Cook, Mohammad Asad, Isabelle Vallerand, Aleksi Suo, Edwin Wang & Tina Cheng. (2022) Comparing the associations between host and tumor factors with survival outcomes with anti‐PD ‐1 immunotherapy in metastatic melanoma . Cancer Medicine 12:3, pages 2427-2439.
Crossref
Jianqing Zheng, Bifen Huang, Lihua Xiao, Min Wu & Jiancheng Li. (2022) Treatment- and immune-related adverse events of immune checkpoint inhibitors in esophageal or gastroesophageal junction cancer: A network meta-analysis of randomized controlled trials. Frontiers in Oncology 12.
Crossref
Irene M. Shui, Emilie Scherrer, Andrew Frederickson, Joyce W. Li, Anel Mynzhassarova, Eric Druyts & Hussein Tawbi. (2022) Resistance to anti-PD1 therapies in patients with advanced melanoma: systematic literature review and application of the Society for Immunotherapy of Cancer Immunotherapy Resistance Taskforce anti-PD1 resistance definitions. Melanoma Research 32:6, pages 393-404.
Crossref
Mafalda Miranda Baleiras, Carolina Vasques, Marta Pinto, Helena Miranda & Ana Martins. (2022) Pembrolizumab-Induced Autoimmune Grade 4 Neutropenia in a Patient With Advanced Bladder Cancer: A Case Report. Cureus.
Crossref
Runzhi He, Xiaoling Zhao, Jianmin Liu, Yajing Zhou, Xiaochong Zhang & Fang Cheng. (2022) PD-1 and CTLA-4 inhibitors in combination vs. alone for the treatment of advanced melanoma: A systematic review and meta-analysis. Medicine 101:41, pages e30561.
Crossref
Léo Plaçais, Stéphane Dalle, Olivier Dereure, Sabiha Trabelsi, Sophie Dalac, Delphine Legoupil, Henri Montaudié, Jean-Philippe Arnault, Julie De Quatrebarbes, Philippe Saiag, Florence Brunet-Possenti, Thierry Lesimple, Eve Maubec, François Aubin, Florence Granel-Brocard, Jean-Jacques Grob, Pierre-Emmanuel Stoebner, Clara Allayous, Bastien Oriano, Caroline Dutriaux, Laurent Mortier & Céleste Lebbe. (2022) Risk of irAEs in patients with autoimmune diseases treated by immune checkpoint inhibitors for stage III or IV melanoma: results from a matched case–control study. Annals of the Rheumatic Diseases 81:10, pages 1445-1452.
Crossref
Qian Sun, Hongyan Sun, Nan Wu, Yue Hu, Fangqing Zhang & Xianling Cong. (2022) Patients with melanoma treated with immune checkpoint inhibitors who had non-thyroid endocrine and skin immune-related adverse events have better prognosis: A systematic review and meta-analysis. Frontiers in Oncology 12.
Crossref
Jarushka Naidoo, Johan F. Vansteenkiste, Corinne Faivre-Finn, Mustafa Özgüroğlu, Shuji Murakami, Rina Hui, Xavier Quantin, Helen Broadhurst, Michael Newton, Piruntha Thiyagarajah & Scott J. Antonia. (2022) Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trial. Lung Cancer 166, pages 84-93.
Crossref
Clémentine Carlet, Stéphane Dalle, Marie-Thérèse Leccia, Laurent Mortier, Sophie Dalac-Rat, Caroline Dutriaux, Delphine Legoupil, Henri Montaudié, Olivier Dereure, Julie De Quatrebarbes, Florence Granel-Brocard, Myrtille Le-Bouar, Julie Charles, Florence Brunet-Possenti, Brigitte Dreno, Wendy Lefevre, Clara Allayous, Céleste Lebbe & Charlée Nardin. (2022) Late-onset adverse events of anti-PD1 therapy in melanoma patients: An observational study from MELBASE, a nationwide prospective cohort. Journal of the American Academy of Dermatology 86:2, pages 345-352.
Crossref
Lina María Serna-Higuita, Teresa Amaral, Andrea Forschner, Ulrike Leiter, Lukas Flatz, Olivia Seeber, Ioannis Thomas, Claus Garbe, Thomas Kurt Eigentler & Peter Martus. (2021) Association between Immune-Related Adverse Events and Survival in 319 Stage IV Melanoma Patients Treated with PD-1-Based Immunotherapy: An Approach Based on Clinical Chemistry. Cancers 13:23, pages 6141.
Crossref
Andrew Nashed, Shijun Zhang, Chien-Wei Chiang, M. Zitu, Gregory A. Otterson, Carolyn J. Presley, Kari Kendra, Sandip H. Patel, Andrew Johns, Mingjia Li, Madison Grogan, Gabrielle Lopez, Dwight H. Owen & Lang Li. (2021) Comparative assessment of manual chart review and ICD claims data in evaluating immunotherapy-related adverse events. Cancer Immunology, Immunotherapy 70:10, pages 2761-2769.
Crossref
Yiting Sun, Liqing Jiang, Ti Wen, Xiaoyu Guo, Xinye Shao, Hui Qu, Xi Chen, Yujia Song, Fang Wang, Xiujuan Qu & Zhi Li. (2021) Trends in the Research Into Immune Checkpoint Blockade by Anti-PD1/PDL1 Antibodies in Cancer Immunotherapy: A Bibliometric Study. Frontiers in Pharmacology 12.
Crossref
Nikhil Atul Shukla, Sandra Althouse, Zachary Meyer, Nasser Hanna & Greg Durm. (2021) Association of Immune-Related Adverse Events and Efficacy Outcomes With Consolidation Pembrolizumab After Chemoradiation in Patients With Inoperable Stage III Non–Small-Cell Lung Cancer. Clinical Lung Cancer 22:4, pages 274-281.
Crossref
Nethanel Asher, Noa Israeli-Weller, Ronnie Shapira-Frommer, Guy Ben-Betzalel, Jacob Schachter, Tomer Meirson & Gal Markel. (2021) Immunotherapy Discontinuation in Metastatic Melanoma: Lessons from Real-Life Clinical Experience. Cancers 13:12, pages 3074.
Crossref
Florentia Dimitriou, Ramon Staeger, Melike Ak, Matias Maissen, Ken Kudura, Marjam J. Barysch, Mitchell P. Levesque, Phil F. Cheng, Reinhard Dummer & Joanna Mangana. (2021) Frequency, Treatment and Outcome of Immune-Related Toxicities in Patients with Immune-Checkpoint Inhibitors for Advanced Melanoma: Results from an Institutional Database Analysis. Cancers 13:12, pages 2931.
Crossref
Qin Zhang, Liansha Tang, Yuwen Zhou, Wenbo He & Weimin Li. (2021) Immune Checkpoint Inhibitor-Associated Pneumonitis in Non-Small Cell Lung Cancer: Current Understanding in Characteristics, Diagnosis, and Management. Frontiers in Immunology 12.
Crossref
Saeka Egami, Hitoshi Kawazoe, Hironobu Hashimoto, Ryuji Uozumi, Toko Arami, Naomi Sakiyama, Yuichiro Ohe, Hideo Nakada, Tohru Aomori, Shinnosuke Ikemura, Koichi Fukunaga, Masakazu Yamaguchi & Tomonori Nakamura. (2021) Absolute Lymphocyte Count Predicts Immune-Related Adverse Events in Patients With Non-Small-Cell Lung Cancer Treated With Nivolumab Monotherapy: A Multicenter Retrospective Study. Frontiers in Oncology 11.
Crossref
Manlio Mencoboni, Marcello Ceppi, Marco Bruzzone, Paola Taveggia, Alessia Cavo, Francesca Scordamaglia, Marina Gualco & Rosa Angela Filiberti. (2021) Effectiveness and Safety of Immune Checkpoint Inhibitors for Patients with Advanced Non Small-Cell Lung Cancer in Real-World: Review and Meta-Analysis. Cancers 13:6, pages 1388.
Crossref
Agnese Paderi, Roberta Giorgione, Elisa Giommoni, Marinella Mela, Virginia Rossi, Laura Doni, Andrea Minervini, Marco Carini, Serena Pillozzi & Lorenzo Antonuzzo. (2021) Association between Immune Related Adverse Events and Outcome in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. Cancers 13:4, pages 860.
Crossref
Alessandro Allegra, Eleonora Di Salvo, Marco Casciaro, Caterina Musolino, Giovanni Pioggia & Sebastiano Gangemi. (2020) The Impact of Immunological Checkpoint Inhibitors and Targeted Therapy on Chronic Pruritus in Cancer Patients. Biomedicines 9:1, pages 2.
Crossref
Claudia Schweizer, Philipp Schubert, Sandra Rutzner, Markus Eckstein, Marlen Haderlein, Sebastian Lettmaier, Sabine Semrau, Antoniu-Oreste Gostian, Benjamin Frey, Udo S. Gaipl, Jian-Guo Zhou, Rainer Fietkau & Markus Hecht. (2020) Prospective evaluation of the prognostic value of immune-related adverse events in patients with non-melanoma solid tumour treated with PD-1/PD-L1 inhibitors alone and in combination with radiotherapy. European Journal of Cancer 140, pages 55-62.
Crossref
Náthali Felícia Mineiro dos Santos Garrett, Ana Cristina Carvalho da Costa, Giovanni Damiani & Christiane Inocêncio Vasques. (2020) Patients with lung cancer undergoing immune checkpoint inhibitors: A meta-analysis of dermatological toxicities. Critical Reviews in Oncology/Hematology 152, pages 102983.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.